Bromodomain-containing protein 1 (BRD1)

Bromodomain-containing protein 1 (BRD1) is a member of the bromodomain protein family, characterized by the presence of a bromodomain that specifically recognizes acetylated lysine residues on histone tails, enabling the regulation of gene transcription through chromatin remodeling. BRD1 acts as a scaffold in the assembly of multi-protein chromatin complexes and exerts broad influence over epigenetic and transcriptional regulation. Dysfunction or altered expression of BRD1 is implicated in the pathogenesis of cancer, neurodevelopmental, and psychiatric disorders. As a member of the wider bromodomain protein class, BRD1 is considered a candidate therapeutic target, particularly as the role of epigenetic readers in disease becomes increasingly understood. Several small molecule inhibitors targeting the bromodomain family are under active investigation, particularly for oncology and inflammatory indications, though none specifically selective for BRD1 have reached clinical approval[1][3][5][6][7].

Other names

BRD1BROMO DOMAIN CONTAINING 1KIAA0368BRD1A

Inhibitors block the interaction between bromodomain and acetylated lysine residues, leading to altered transcriptional programs, especially silencing genes involved in proliferation and inflammation